Ubs Group Ag Black Diamond Therapeutics, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 38,457 shares of BDTX stock, worth $95,757. This represents 0.0% of its overall portfolio holdings.

Number of Shares

38,457

Previous 26,534 44.93%

Holding current value

$95,757

Previous $123,000 35.77%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$4.2 - $6.58 $50,076 - $78,453	11,923 Added 44.93%	38,457 $167,000
Q2 2024 Aug 13, 2024	BUY	$4.65 - $7.39 $103,522 - $164,523	22,263 Added 521.26%	26,534 $123,000
Q1 2024 May 13, 2024	BUY	$2.67 - $5.74 $758 - $1,630	284 Added 7.12%	4,271 $21,000
Q4 2023 Feb 09, 2024	BUY	$1.77 - $3.03 $6,621 - $11,335	3,741 Added 1520.73%	3,987 $11,000
Q3 2023 Nov 09, 2023	SELL	$2.87 - $4.99 $23,743 - $41,282	-8,273 Reduced 97.11%	246 $0
Q2 2023 Aug 11, 2023	BUY	$1.43 - $6.18 $12,182 - $52,647	8,519 New	8,519 $43,000
Q4 2022 Feb 08, 2023	SELL	$1.27 - $2.51 $2,466 - $4,874	-1,942 Reduced 36.13%	3,433 $6,000
Q3 2022 Nov 10, 2022	SELL	$1.68 - $4.01 $20,536 - $49,018	-12,224 Reduced 69.46%	5,375 $9,000
Q2 2022 Aug 10, 2022	SELL	$1.5 - $3.63 $4,831 - $11,692	-3,221 Reduced 15.47%	17,599 $44,000
Q1 2022 May 16, 2022	SELL	$2.66 - $5.61 $23,232 - $48,997	-8,734 Reduced 29.55%	20,820 $58,000
Q4 2021 Feb 14, 2022	BUY	$5.18 - $8.48 $65,956 - $107,975	12,733 Added 75.7%	29,554 $157,000
Q3 2021 Nov 15, 2021	BUY	$8.46 - $12.42 $46,140 - $67,738	5,454 Added 47.98%	16,821 $143,000
Q2 2021 Aug 13, 2021	SELL	$12.19 - $28.17 $387,910 - $896,425	-31,822 Reduced 73.68%	11,367 $139,000
Q1 2021 May 12, 2021	BUY	$22.23 - $34.75 $960,091 - $1.5 Million	43,189 New	43,189 $1.05 Million
Q4 2020 Feb 11, 2021	SELL	$29.47 - $35.0 $5,805 - $6,895	-197 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$26.17 - $43.07 $116,639 - $191,962	-4,457 Reduced 95.77%	197 $6,000
Q2 2020 Jul 31, 2020	SELL	$22.3 - $44.8 $57,467 - $115,449	-2,577 Reduced 35.64%	4,654 $196,000
Q1 2020 May 01, 2020	BUY	$18.18 - $39.48 $131,459 - $285,479	7,231 New	7,231 $180,000

Others Institutions Holding BDTX

# of Institutions

117

Shares Held

48.8M

Call Options Held

1.84M

Put Options Held

1.93M

View Full List

About Black Diamond Therapeutics, Inc.

Ticker BDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,339,500
Market Cap $90.5M
Description
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...

More about BDTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account